Evocalcet

DB12388InvestigationalSmall molecule

Evocalcet has been used in trials studying the treatment of Hyperparathyroidism and Secondary Hyperparathyroidism.

Mechanism: Pharmacologically active on Extracellular calcium-sensing receptor
Curator reviewed
Formula / weight: C₂₄H₂₆N₂O₂ · 374.484 g/mol (avg)
Code names: KHK-7580 · MT-4580

Resolves to

Compound

Clinical / RWD

Structure

InChIKeyRZNUIYPHQFXBAN-XLIONFOSSA-NSMILESC[C@@H](N[C@H]1CCN(C1)C1=CC=C(CC(O)=O)C=C1)C1=C2C=CC=CC2=CC=C1

Targets

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

6Clinical trialsPhase, status and sponsor resolved per trial

1ATC codeIncluding every combination product, plus 3 drug categories

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Evocalcet, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.